Annovis Bio (NYSE:ANVS) Posts Earnings Results, Misses Estimates By $0.05 EPS

Annovis Bio (NYSE:ANVS) announced its quarterly earnings results on Friday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), Zacks reports. During the same quarter in the previous year, the company earned ($0.43) EPS.

Annovis Bio Price Performance

Shares of NYSE:ANVS opened at $1.77 on Friday. Annovis Bio has a 1 year low of $1.53 and a 1 year high of $20.00. The business has a 50 day simple moving average of $2.99 and a two-hundred day simple moving average of $5.75. The firm has a market capitalization of $25.13 million, a PE ratio of -0.40 and a beta of 1.65.

Analysts Set New Price Targets

Separately, D. Boral Capital restated a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $37.00.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.